Devonian Health Group Inc. (CVE:GSD – Get Free Report)’s share price traded up 8.8% on Wednesday . The stock traded as high as C$9.27 and last traded at C$9.25. 404 shares changed hands during mid-day trading, a decline of 66% from the average session volume of 1,197 shares. The stock had previously closed at C$8.50.
Devonian Health Group Price Performance
The stock has a 50-day simple moving average of C$9.43 and a 200 day simple moving average of C$10.94. The company has a market cap of C$28.20 million, a PE ratio of -4.51 and a beta of 0.44. The company has a quick ratio of 7.82, a current ratio of 1.07 and a debt-to-equity ratio of 16.36.
Devonian Health Group Company Profile
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.
Featured Articles
- Five stocks we like better than Devonian Health Group
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
